Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OD-07656 and Vedolizumab in Ulcerative Colitis
NCT06850727Phase 2Recruiting
- Sponsor
- Odyssey Therapeutics
- Start
- Jun 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of OD-07656 in ulcerative colitis (UC) (3 arms), sponsored by Odyssey Therapeutics. Primary endpoints: Change in 3-component modified Mayo Clinic Score at 12 weeks and Incidence of treatment-emergent adverse events at 12 weeks. Started Jun 2025; status: recruiting.
02
Drugs
OD-07656
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06850727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06850727.